Evotec has entered into an agreement with Merck to develop pre-clinical candidates for an undisclosed neurological disease.

Evotec will provide its drug research expertise in the areas of medicinal chemistry, vitro biology, in vitro and in vivo pharmacology to identify interesting small molecules for the selected target.

The molecules will be further optimised and advanced using lead optimisation to develop a pre-clinical candidate.